Sanofi Global Operations President Hanspeter Spek On Building A Diversified Strategy In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

06 Apr 2012

• By Joshua Berlin and Jialing Dai

In an interview in Shanghai, the senior Sanofi exec talks about the company’s diversified strategy in emerging markets, affordability issues and the French pharma’s partnering aspirations in China.

SHANGHAI – As a diversified company, Sanofi has risen to become the top pharma company in emerging markets with 2011 sales for the first time exceeding €10 billion, backed by its top position in Brazil and number two position in China and Russia.

Despite facing one of the steepest patent cliffs in the industry, Sanofi is looking to the future by focusing on a world where sustainable growth will be fueled by products...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

28 May 2025

• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.